Pharmanovia has signed an exclusive distribution agreement with Er-Kim, to enhance the availability of Sunosi (Solriamfetol), a first-in-class treatment for Excessive Daytime Sleepiness (EDS), in 14 countries across Eastern Europe.
Under the terms of the agreement, Er-Kim will be responsible for launching and commercialising Sunosi (Solriamfetol) in the following markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia. Pharmanovia will retain the marketing authorisation for the product in these territories.
“Sunosi® (Solriamfetol) represents an important advancement in the treatment of EDS, with proven clinical efficacy and a unique mechanism of action,” said Dr. James Burt, CEO, Pharmanovia. “Our primary goal is to ensure that as many patients as possible gain access to this efficacious therapy. With Er-Kim as our partner across CEE, we have identified a team with an in-depth understanding of the region and the expertise to bring innovative treatments to the CEE market.”
Cem Zorlular, CEO of Er-Kim, said: “We are thrilled to have been selected as the exclusive launch partner for Sunosi® (Solriamfetol) in the CEE region and excited to work with Pharmanovia. This is a highly innovative treatment, and its successful introduction requires a partner with deep market knowledge and capability in navigating the regulatory, medical and commercial landscapes of these diverse markets. We are excited to work together with Pharmanovia to ensure patients in need can benefit from this important medicine.”
